4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer

Molecular Oncology

Volumn 10, Issue 1, 2016, Pages 24-39

  De Marchi, Tommaso ^a,b   Liu, Ning Qing ^a,g   Stingl, Cristoph ^b   Timmermans, Mieke A ^a   Smid, Marcel ^a   Look, Maxime P ^a   Tjoa, Mila ^a   Braakman, Rene B H ^a,b   Opdam, Mark ^c   Linn, Sabine C ^c   Sweep, Fred C G J ^d   Span, Paul N ^d   Kliffen, Mike ^e   Luider, Theo M ^b   Foekens, John A ^a   Martens, John W M ^a,f   Umar, Arzu ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Maasstad Hospital Rotterdam   (Netherlands)

^f Cancer Genomics Center Netherlands   (Netherlands)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarker; Breast cancer; Mass spectrometry; Proteomics; Tamoxifen resistance

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RESISTANCE; CONTROLLED STUDY; EPITHELIUM CELL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; TREATMENT OUTCOME; BREAST NEOPLASMS; CLASSIFICATION; FEMALE; METABOLISM; MIDDLE AGED; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84953368340     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.07.004     Document Type: Article

References (53)

1. Altman D.G., McShane L.M., Sauerbrei W., Taube S.E. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012, 9:e1001216. 10.1371/journal.pmed.1001216.
2. Beelen K., Zwart W., Linn S.C. Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. Nat. Rev. Clin. Oncol. 2012, 9:529-541. 10.1038/nrclinonc.2012.121.
3. Biyanee A., Ohnheiser J., Singh P., Klempnauer K.-H. A novel mechanism for the control of translation of specific mRNAs by tumor suppressor protein Pdcd4: inhibition of translation elongation. Oncogene 2014, 1-9. 10.1038/onc.2014.83.
4. Bland J., Altman D. Measurement error proportional to the mean. BMJ Br. Med. J. 1996, 313:1996.
5. Braakman R.B.H., Tilanus-Linthorst M.M., Liu N.Q., Stingl C., Dekker L.J.M., Luider T.M., Martens J.W.M., Foekens J.A., Umar A. Optimized nLC-MS workflow for laser capture microdissected breast cancer tissue. J. Proteomics 2012, 75:2844-2854. 10.1016/j.jprot.2012.01.022.
6. Cardoso F., Harbeck N., Fallowfield L., Kyriakides S., Senkus E. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012, 23(Suppl. 7):vii11-vii19. 10.1093/annonc/mds232.
7. Cheng L., Zhang S. Laser-assisted microdissection in translational research: theory, technical considerations, and future applications. Appl. Immunohistochem. Mol. Morphol. 2013, 21:31-47.
8. Chung L., Baxter R.C. Breast cancer biomarkers: proteomic discovery and translation to clinically relevant assays. Expert Rev. Proteomics 2012, 9:599-614. 10.1586/epr.12.62.
9. Citi S., Amorosi A., Franconi F. Cingulin, a specific protein component of tight junctions, is expressed in normal and neoplastic human epithelial tissues. Am. J. Pathol. 1991, 138:781-789.
10. Clark A.S., West K., Streicher S., Dennis P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 2002, 1:707-717.
11. Cox J., Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008, 26:1367-1372. 10.1038/nbt.1511.
12. Cox J., Neuhauser N., Michalski A., Scheltema R.A., Olsen J.V., Mann M. Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 2011, 10:1794-1805. 10.1021/pr101065j.
13. Den Boon J.A., Pyeon D., Wang S.S., Horswill M., Schiffman M., Sherman M., Zuna R.E., Wang Z., Hewitt S.M., Pearson R., Schott M., Chung L., He Q., Lambert P., Walker J., Newton M.A., Wentzensen N., Ahlquist P. Molecular transitions from papillomavirus infection to cervical precancer and cancer: role of stromal estrogen receptor signaling. Proc. Natl. Acad. Sci. 2015, 201509322. 10.1073/pnas.1509322112.
14. Drabovich A.P., Martínez-Morillo E., Diamandis E.P. Toward an integrated pipeline for protein biomarker development. Biochim. Biophys. Acta 2014, 10.1016/j.bbapap.2014.09.006.
15. Droog M., Beelen K., Linn S., Zwart W. Tamoxifen resistance: from bench to bedside. Eur. J. Pharmacol. 2013, 1-11. 10.1016/j.ejphar.2012.11.071.
16. Emmert-buck M.R., Bonner R.F., Smith P.D., Chuaqui R.F., Zhuang Z., Goldstein S.R., Weiss R.A., Liotta L.A. Laser capture microdissection. Science 1996, 274:8-11.
17. Grebe S., Singh R. LC-MS/MS in the clinical laboratory-where to from here?. Clin. Biochem. Rev. 2011, 32:5-31.
18. Guillemot L., Spadaro D., Citi S. The junctional proteins cingulin and paracingulin modulate the expression of tight junction protein genes through GATA-4. PLoS One 2013, 8:e55873. 10.1371/journal.pone.0055873.
19. Hayward J., Carbone P. Assessment of response to therapy in advanced breast cancer. Cancer 1977, 39:1289-1294.
20. Huang B.D.W., Lempicki R. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2008, 1-43.
21. Huang D.W., Sherman B.T., Lempicki R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009, 37:1-13. 10.1093/nar/gkn923.
22. Johnson W.E., Li C., Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007, 8:118-127. 10.1093/biostatistics/kxj037.
23. Jung Y.Y., Lee Y.K., Koo J.S. Expression of cancer-associated fibroblast-related proteins in adipose stroma of breast cancer. Tumor Biol. 2015, 10.1007/s13277-015-3594-9.
24. Kim M.-S., Pinto S.M., Getnet D., Nirujogi R.S., Manda S.S., Chaerkady R., Madugundu A.K., Kelkar D.S., Isserlin R., Jain S., Thomas J.K., Muthusamy B., Leal-Rojas P., Kumar P., Sahasrabuddhe N.A., Balakrishnan L., Advani J., George B., Renuse S., Selvan L.D.N., Patil A.H., Nanjappa V., Radhakrishnan A., Prasad S., Subbannayya T., Raju R., Kumar M., Sreenivasamurthy S.K., Marimuthu A., Sathe G.J., Chavan S., Datta K.K., Subbannayya Y., Sahu A., Yelamanchi S.D., Jayaram S., Rajagopalan P., Sharma J., Murthy K.R., Syed N., Goel R., Khan A.A., Ahmad S., Dey G., Mudgal K., Chatterjee A., Huang T.-C., Zhong J., Wu X., Shaw P.G., Freed D., Zahari M.S., Mukherjee K.K., Shankar S., Mahadevan A., Lam H., Mitchell C.J., Shankar S.K., Satishchandra P., Schroeder J.T., Sirdeshmukh R., Maitra A., Leach S.D., Drake C.G., Halushka M.K., Prasad T.S.K., Hruban R.H., Kerr C.L., Bader G.D., Iacobuzio-Donahue C.A., Gowda H., Pandey A. A draft map of the human proteome. Nature 2014, 509:575-581. 10.1038/nature13302.
25. Klinge C.M. miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets. Mol. Cell. Endocrinol 2015, 10.1016/j.mce.2015.01.035.
26. Klinge C.M., Riggs K.A., Wickramasinghe N.S., Emberts C.G., McConda D.B., Barry P.N., Magnusen J.E. Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription. Mol. Cell. Endocrinol 2010, 323:268-276. 10.1016/j.mce.2010.03.013.
27. Kociok N., Esser P., Unfried K., Parker F., Schraermeyer U., Grisanti S., Toqué B., Heimann K. Upregulation of the RAS-GTPase activating protein (GAP)-binding protein (G3BP) in proliferating RPE cells. J. Cell. Biochem 1999, 74:194-201.
28. Kondo T. Inconvenient truth: cancer biomarker development by using proteomics. Biochim. Biophys. Acta 2014, 1844:861-865. 10.1016/j.bbapap.2013.07.009.
29. Lankat-Buttgereit B., Göke R. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biol. Cell 2009, 101:309-317. 10.1042/BC20080191.
30. Lee J., Kim J.C.K., Lee S.-E., Quinley C., Kim H., Herdman S., Corr M., Raz E. Signal transducer and activator of transcription 3 (STAT3) protein suppresses adenoma-to-carcinoma transition in Apcmin/+ mice via regulation of Snail-1 (SNAI) protein stability. J. Biol. Chem. 2012, 287:18182-18189. 10.1074/jbc.M111.328831.
31. Liu N.Q., Braakman R.B.H., Stingl C., Luider T.M., Martens J.W.M., Foekens J.A., Umar A. Proteomics pipeline for biomarker discovery of laser capture microdissected breast cancer tissue. J. Mammary Gland Biol. Neoplasia 2012, 17:155-164. 10.1007/s10911-012-9252-6.
32. Liu N.Q., Stingl C., Look M.P., Smid M., Braakman R.B.H., De Marchi T., Sieuwerts A.M., Span P.N., Sweep F.C.G.J., Linderholm B.K., Mangia A., Paradiso A., Dirix L.Y., Van Laere S.J., Luider T.M., Martens J.W.M., Foekens J.a, Umar A. Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer. J. Natl. Cancer Inst. 2014, 10.1093/jnci/djt376.
33. Manavalan T.T., Teng Y., Appana S.N., Datta S., Kalbfleisch T.S., Li Y., Klinge C.M. Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. Cancer Lett. 2011, 313:26-43. 10.1016/j.canlet.2011.08.018.
34. Matsuki H., Takahashi M., Higuchi M., Makokha G.N., Oie M., Fujii M. Both G3BP1 and G3BP2 contribute to stress granule formation. Genes Cells 2013, 18:135-146. 10.1111/gtc.12023.
35. Megger D., Bracht T., Meyer H., Sitek B. Label-free quantification in clinical proteomics. Biochim. Biophys. Acta 2013, 1834:1581-1590.
36. Milani A. Overcoming endocrine resistance in metastatic breast cancer: current evidence and future directions. World J. Clin. Oncol. 2014, 5:990. 10.5306/wjco.v5.i5.990.
37. Musteanu M., Blaas L., Mair M., Schlederer M., Bilban M., Tauber S., Esterbauer H., Mueller M., Casanova E., Kenner L., Poli V., Eferl R. Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology 2010, 138:1003-1011. e1-5. 10.1053/j.gastro.2009.11.049.
38. Nass N., Kalinski T. Tamoxifen resistance: from cell culture experiments towards novel biomarkers. Pathol. Res. Pract. 2015, 211:189-197. 10.1016/j.prp.2015.01.004.
39. Palamarchuk A., Efanov A., Maximov V., Aqeilan R.I., Croce C.M., Pekarsky Y. Akt phosphorylates and regulates Pdcd4 tumor suppressor protein. Cancer Res. 2005, 65:11282-11286. 10.1158/0008-5472.CAN-05-3469.
40. Paschoud S., Bongiovanni M., Pache J.-C., Citi S. Claudin-1 and claudin-5 expression patterns differentiate lung squamous cell carcinomas from adenocarcinomas. Mod. Pathol. 2007, 20:947-954. 10.1038/modpathol.3800835.
41. Sengupta S., Michener C.M., Escobar P., Belinson J., Ganapathi R. Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion. Gynecol. Oncol. 2008, 109:226-233. 10.1016/j.ygyno.2007.12.024.
42. Sereni M.I., Baldelli E., Gambara G., Deng J., Zanotti L., Bandiera E., Bignotti E., Ragnoli M., Tognon G., Ravaggi A., Meani F., Memo M., Angioli R., Liotta L.a, Pecorelli S.L., Petricoin E., Pierobon M. Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy. Proteomics 2015, 15:365-373. 10.1002/pmic.201400214.
43. Sinha A., Khadilkar R.J., S V.K., Roychowdhury Sinha A., Inamdar M.S. Conserved regulation of the Jak/STAT pathway by the endosomal protein asrij maintains stem cell potency. Cell Rep. 2013, 4:649-658. 10.1016/j.celrep.2013.07.029.
44. Vizcaíno J.A., Côté R.G., Csordas A., Dianes J.A., Fabregat A., Foster J.M., Griss J., Alpi E., Birim M., Contell J., O'Kelly G., Schoenegger A., Ovelleiro D., Pérez-Riverol Y., Reisinger F., Ríos D., Wang R., Hermjakob H. The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 2013, 41:D1063-D1069. 10.1093/nar/gks1262.
45. Vogel A., Lorenz K., Horneffer V., Hüttmann G., von Smolinski D., Gebert A. Mechanisms of laser-induced dissection and transport of histologic specimens. Biophys. J. 2007, 93:4481-4500. 10.1529/biophysj.106.102277.
46. Whiteaker J.R., Lin C., Kennedy J., Hou L., Trute M., Sokal I., Yan P., Schoenherr R.M., Zhao L., Voytovich U.J., Kelly-Spratt K.S., Krasnoselsky A., Gafken P.R., Hogan J.M., Jones L.A., Wang P., Amon L., Chodosh L.A., Nelson P.S., McIntosh M.W., Kemp C.J., Paulovich A.G. A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat. Biotechnol. 2011, 29:625-634. 10.1038/nbt.1900.
47. Wilhelm M., Schlegl J., Hahne H., Gholami A.M., Lieberenz M., Savitski M.M., Ziegler E., Butzmann L., Gessulat S., Marx H., Mathieson T., Lemeer S., Schnatbaum K., Reimer U., Wenschuh H., Mollenhauer M., Slotta-Huspenina J., Boese J.-H., Bantscheff M., Gerstmair A., Faerber F., Kuster B. Mass-spectrometry-based draft of the human proteome. Nature 2014, 509:582-587. 10.1038/nature13319.
48. Winslow S., Leandersson K., Larsson C. Regulation of PMP22 mRNA by G3BP1 affects cell proliferation in breast cancer cells. Mol. Cancer 2013, 12:156. 10.1186/1476-4598-12-156.
49. Xu B.J. Combining laser capture microdissection and proteomics: methodologies and clinical applications. Proteomics Clin. Appl. 2010, 4:116-123. 10.1002/prca.200900138.
50. Yang F., Foekens J.A., Yu J., Sieuwerts A.M., Timmermans M., Klijn J.G., Atkins D., Wang Y., Jiang Y. Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways. Oncogene 2006, 25:1413-1419. 10.1038/sj.onc.1209165.
51. Yang H., Matthews C., Clair T. Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion. Mol. Cell. Biol. 2006, 10.1128/MCB.26.4.1297.
52. Yang A.-H., Chen J.-Y., Lee C.-H., Chen J.-Y. Expression of NCAM and OCIAD1 in well-differentiated thyroid carcinoma: correlation with the risk of distant metastasis. J. Clin. Pathol. 2012, 65:206-212. 10.1136/jclinpath-2011-200416.
53. Yassine H., Borges C.R., Schaab M.R., Billheimer D., Stump C., Reaven P., Lau S.S., Nelson R. Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes. Proteomics Clin. Appl. 2013, 7:528-540. 10.1002/prca.201200028.